Last night, after the close, the Instant Scanner went hunting again.
Nearly a thousand of America’s biggest stocks. Four strict checks.
Most nights, only a handful survive.
What’s left is the short list – each stock with an exact buy price and a defined 10-day exit.
Scanner owners had that list in front of them in minutes.
No charts. No digging. No wondering what they missed.
The same scan runs again tonight.
In my Black Friday sale, a full year of it is $7 instead of $247.
One payment. No re-bills.
Good Trading,
Bill Poulos
P.S. Tonight’s list gets built either way. $7 puts it on your screen.
Novo Nordisk’s Real Test Is Not in Washington. It Is at the FDA.
Novo Nordisk spent four days at ObesityWeek 2026 in Washington methodically widening the clinical argument for CagriSema. The data were genuine, the bone-preservation finding was novel, and the food-noise numbers gave Wegovy a real-world behavioral story it had never had before. None of it settles what actually matters for NVO at $41.60: whether the FDA grants CagriSema its first U.S. approval before 2026 ends.
Markets are treating this week correctly so far. NVO shares rose 2.7% in Copenhagen on Monday after the company presented the new data. That is a sentiment reaction, not a re-rating. The 52-week range still runs from $35.12 to $64.16, and the stock sits in the lower half of it. The conference gave traders a reason to cover, not a reason to reload.
What the Data Actually Said
In the REDEFINE 9 trial, patients receiving 1 mg and 1.7 mg weekly doses lost 21% and 20.7% of their body weight respectively at week 68. Patients receiving placebo lost 2% of their body weight. That is the lower-dose story: even at sub-maximum doses, CagriSema produces weight loss that significantly exceeds Wegovy alone.
In a post hoc analysis of the REDEFINE 1 trial, 67.8% of adults treated with CagriSema 2.4 mg/2.4 mg were early responders, achieving at least 5% weight loss by week 8, with that group ultimately averaging roughly 25% total loss. The post hoc framing matters: these are not prospective primary endpoints. They add texture, not regulatory weight.
In the SIGNAL study, which included more than 26,000 treatment-naive adults, food noise scores declined significantly within the first month of starting injectable semaglutide, with the greatest improvements observed during the first three months and maintained through six months. The OCTANE study found that adults taking oral semaglutide experienced about a 25% reduction in average food noise scores after three months.
The bone data, presented November 16, carried a different clinical argument. In small clinical studies in humans, cagrilintide and zenagamtide suppressed CTX-I, a biomarker of bone resorption, while NN1213, a selective amylin receptor agonist that activates the amylin receptor but not the calcitonin receptor, was not associated with the same effect. Molecules that activate both the amylin and calcitonin receptors showed effects consistent with reduced bone loss, results that support further study of dual receptor agonism during weight loss. This is a preclinical-plus-biomarker signal, not an outcomes trial. It matters for the pipeline, less so for the pending NDA.
The Regulatory Event Traders Should Be Watching
Novo Nordisk submitted a New Drug Application to the FDA in December 2025 for CagriSema 2.4 mg/2.4 mg for weight management, with a regulatory decision expected in the fourth quarter of 2026. That clock is running. ObesityWeek data builds the clinical and commercial case for a drug that is already under review; it does not accelerate or alter the FDA’s timeline. What the data do not do is settle the regulatory question. The next milestone remains the anticipated FDA decision in Q4 2026, covering the higher dose the company has applied for.
If approved, Novo “will set the first regulatory and pricing reference for the class before either Lilly or Roche reaches their respective Phase 3 readout,” according to Rodman and Renshaw. That is a meaningful first-mover position in a category where label language and launch price become the competitive floor.
First-mover advantage in GLP-1 weight loss depends on more than a single approval. Viking Therapeutics is advancing two fully enrolled Phase 3 trials in the same obesity market Novo is racing to lock up.
Options Market Analysis
NVO’s at-the-money implied volatility is approximately 42% for the December 4 expiration, against 22% realized volatility over the last 30 trading days, a nearly 20-point volatility premium. IV rank sits at 39 and IV percentile at 46 over the past 252 sessions, with the 52-week range running from 25% to 67%. The IV/HV spread confirms the market is pricing event risk, not a stable grind. Options are not cheap, but they are not at the kind of elevated rank where premium selling becomes the reflexive default.
The December expiration captures the FDA decision window. At current IV, the options market is embedding a move of roughly plus or minus 8 to 9 percent through year-end. Given that NVO historically moves an average of about 5% on major binary catalysts, the market is pricing in some tail.
Structured Trade Framework
Bull case: If you believe FDA approval arrives in Q4, a defined-risk long call spread in December expiration, buying the $43 call and selling the $48 call, keeps net debit below $1.50 and targets the analyst consensus around $45.52. The structure limits exposure to premium paid if approval is delayed into 2027.
Bear case: For traders expecting a complete response letter or label complications, a long put spread buying the $40 put and selling the $36 put in December limits cost while expressing downside toward the March 2026 lows near $35. A CRL outcome would likely gap the stock through that level, so defined risk here protects against an overshoot in either direction.
Neutral case: With IV rank in the mid-range and a known binary outcome approaching, an iron condor centered around current price with the $36/$38 put spread and $45/$47 call spread collects premium while defining risk on both wings. This structure profits if the FDA decision is delayed past December expiration and the stock drifts sideways.
Risk Analysis
The primary risk is a CRL on safety or labeling grounds that the ObesityWeek data cannot mitigate. Secondary risk: approval arrives but the label carries restrictions that limit addressable population relative to Wegovy’s current indication. Novo reported 4% constant-currency sales growth in Q3, and adjusted operating profit rose 27%, while management raised its full-year outlook to -2% to +2% for both adjusted sales growth and adjusted operating profit growth at constant exchange rates. The underlying business is not in distress; the stock’s near-70% decline from its June 2024 closing high of $137.40 already prices considerable skepticism about CagriSema’s commercial ceiling.
Action Checklist
- Mark Q4 2026 FDA decision window as the primary volatility trigger, not conference data
- Monitor IV expansion in December expiration as the decision date firms; a spike above IV rank 60 favors premium selling structures
- Track CagriSema label scope if approval comes: cardiovascular indication inclusion or exclusion will determine competitive positioning against Lilly
- Defined-risk structures are preferred over outright long calls given the binary outcome and elevated IV/HV spread
- Watch the $38 level on NVO as near-term support; a close below it on no FDA news would indicate broad sentiment deterioration, not a catalyst trade
